Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease

被引:2
作者
Soosanabadi, Mohsen [1 ]
Ghahfarokhi, Arezoo Mosharraf [2 ]
Pourghazi, Farzad [3 ]
Ehtesham, Naeim [1 ]
Mirfakhraie, Reza [4 ]
Atanesyan, Lilit [5 ]
Keyhani, Elahe [6 ]
Behjati, Farkhondeh [7 ,8 ,9 ]
机构
[1] Semnan Univ Med Sci, Dept Med Genet, Semnan, Iran
[2] Shahid Beheshti Univ, Fac Life Sci & Technol, Dept Cellular & Mol Biol, Tehran, Iran
[3] Univ Tehran Med Sci, Fac Med, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Fac Med, Dept Med Genet, Tehran, Iran
[5] MRC Holland BV, Amsterdam, Netherlands
[6] Rofeideh Rehabil Hosp, Clin Res Dev Ctr, Tehran, Iran
[7] Univ Social Welf & Rehabil Sci, Genet Res Ctr, Tehran, Iran
[8] Iran Univ Med Sci IUMS, Sarem Womens Hosp, Sarem Fertil & Infertil Res Ctr SAFIR, Tehran, Iran
[9] Sarem Womens Hosp, Sarem Cell Res Ctr SCRC, Tehran, Iran
关键词
Breast cancer; ERBB gene; mRNA expression; Prognosis; EGFR FAMILY; RECEPTORS; HER-2; OVEREXPRESSION; AMPLIFICATION; SURVIVAL;
D O I
10.1007/s11033-022-07684-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background Breast cancer (BC) is the most prevalent and fatal cancer in women. Given that there are very few studies investigating the overexpression of four members of ERBB genes, we decided to investigate the correlation between these four genes with clinicopathological characteristics in breast cancer cases. Methods Tumoural tissue of 50 patients with sporadic invasive ductal BC was recruited. Also, control samples were provided from adjacent non-cancerous tissues (ANCTs) of the same patients. The expression of four ERBB genes was evaluated by real-time PCR and its correlation with clinicopathological characteristics was assessed. Results Only ERBB2 (HER2) was overexpressed in tumoural tissue compared with ANCTs. Our data showed a significant relationship between ERBB1 overexpression with triple-negative tumors, ER, and PR negativity (P < 0.05). Also, ERBB2 overexpression indicated a significant correlation with several pathological characteristics such as age < 50, tumor size larger than 2 cm, early and advanced stages, negative involved lymph nodes, luminal B, triple-negative, ERBB2-enrich, estrogen receptor (ER) and progesterone receptor (PR) negative tumors, Ki-67 mutation more than 15%, and finally HER2/neu immunohistochemistry (IHC) positive and intermediate (P < 0.05). Moreover, this study demonstrated that ERBB4 overexpression had a significant correlation with tumor size smaller than 2 cm, grade I and II tumors (early-stage tumors), luminal A, ER and PR positive tumors, HER-2/neu IHC intermediate, and tumors that had a Ki-67 mutation lower than 15% (P < 0.05). Besides, our analysis showed a significant correlation between the expression of ERBB1 with ERBB2 and ERBB3 with ERBB4 (P < 0.05). Conclusions Our findings showed a significant relationship between unfavorable clinicopathological characteristics with ERBB1 and ERBB2 overexpression, but overexpression of ERBB4 was correlated with favorable outcomes.
引用
收藏
页码:8547 / 8553
页数:7
相关论文
共 35 条
  • [1] Breast Cancer Statistics: Recent Trends
    Ahmad, Aamir
    [J]. BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS, 2ND EDITION, 2019, 1152 : 1 - 7
  • [2] Ansquer Y, 2005, ANTICANCER RES, V25, P4535
  • [3] Role of ErbB Receptors in Cancer Cell Migration and Invasion
    Appert-Collin, Aline
    Hubert, Pierre
    Cremel, Gerard
    Bennasroune, Amar
    [J]. FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [4] Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer
    Atalay, G
    Cardoso, F
    Awada, A
    Piccart, MJ
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (09) : 1346 - 1363
  • [5] Azizun-Nisa, 2008, ASIAN PAC J CANCER P, V9, P553
  • [6] Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast
    Barnes, NLP
    Khavari, S
    Boland, GP
    Cramer, A
    Knox, WF
    Bundred, NJ
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (06) : 2163 - 2168
  • [7] Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
    Barros, Fabricio F. T.
    Powe, Desmond G.
    Ellis, Ian O.
    Green, Andrew R.
    [J]. HISTOPATHOLOGY, 2010, 56 (05) : 560 - 572
  • [8] Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration
    Bray, F.
    Ferlay, J.
    Laversanne, M.
    Brewster, D. H.
    Mbalawa, C. Gombe
    Kohler, B.
    Pineros, M.
    Steliarova-Foucher, E.
    Swaminathan, R.
    Antoni, S.
    Soerjomataram, I.
    Forman, D.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (09) : 2060 - 2071
  • [9] HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival A Study of 4046 Patients
    Chiu, Connie G.
    Masoudi, Hamid
    Leung, Samuel
    Voduc, David K.
    Gilks, Blake
    Huntsman, David G.
    Wiseman, Sam M.
    [J]. ANNALS OF SURGERY, 2010, 251 (06) : 1107 - 1116
  • [10] Dang Cong Thuan, 2020, Asian Pac J Cancer Prev, V21, P1135, DOI 10.31557/APJCP.2020.21.4.1135